

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO SECTION 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of October, 2018

Commission File Number: 001-36815

---

**Ascendis Pharma A/S**  
(Exact Name of Registrant as Specified in Its Charter)

---

**Tuborg Boulevard 12  
DK-2900 Hellerup  
Denmark**  
(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

## INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843 and 333-216883) and Form F-3 (Registration Numbers 333-209336, 333-211511, 333-216882, 333-223134 and 333-225284) of Ascendis Pharma A/S (the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

---

On October 1, 2018, the Company completed enrollment in its fliGHt Trial (switch trial) evaluating TransCon Growth Hormone in subjects previously treated with a daily growth hormone therapy. The final enrollment in the fliGHt Trial is 146 subjects ranging from 1 to 17 years of age, predominantly in the United States. Combining these subjects with the previously enrolled 161 subjects in the Company’s pivotal heiGHt Trial, total enrollment in the ongoing phase 3 program for TransCon Growth Hormone is now over 300 subjects. Subjects completing either the heiGHt or fliGHt Trials may also enroll in the enliGHten Trial, an open-label long-term extension trial evaluating TransCon Growth Hormone.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 2, 2018

**Ascendis Pharma A/S**

By: /s/ Michael Wolff Jensen

Michael Wolff Jensen

Senior Vice President, General Counsel